Synovial Sarcoma

The FDA granted accelerated approval to afamitresgene autoleucel for certain adults with unresectable or metastatic synovial sarcoma.

In this video, Candace Haddox, MD, discussed a few presentations from the Connective Tissue Oncology Society Annual Meeting that focused on how better understanding of sarcoma biology could lead to clinical advancement.

Half of patients with relapsed or refractory solid tumors achieved objective response to an infusion of IMA203, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

Nearly 40% of patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma responded to therapy with afamitresgene autoleucel, according to results of a phase 2 study.

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Soft tissue sarcoma is a rare type of cancer that affects the body’s soft tissues, such as muscles, fat and ligaments. There are more than 50 types of soft tissue sarcoma, including synovial sarcoma, which accounts for 5% to 10% of all soft tissue tumors diagnosed each year.

The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas.